Crawford, J., Lubaczewski, S. L., Tarachandani, A., Harrington, M. A., Weng, Y., Qiu, R., … Revkin, J. H. (2023). Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Crawford, Jeffrey, Shannon L. Lubaczewski, Anil Tarachandani, Magdalena A. Harrington, Yan Weng, Ruolun Qiu, Susie M. Collins, Michelle I. Rossulek, and James H. Revkin. “Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Crawford J, Lubaczewski SL, Tarachandani A, Harrington MA, Weng Y, Qiu R, et al. Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Crawford, Jeffrey, et al. “Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Crawford J, Lubaczewski SL, Tarachandani A, Harrington MA, Weng Y, Qiu R, Collins SM, Rossulek MI, Revkin JH. Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. JOURNAL OF CLINICAL ONCOLOGY. 2023.